Scarica l'app Stockscreener
2.26
8.13%
0.17
Dopo l'orario di chiusura:
2.26
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Anheuser-Busch InBev S.A. ADR falls Tuesday, underperforms market - MSN
Adagene shares downgraded to hold, target cut to $3.50 - Investing.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat
Anheuser-Busch InBev S.A. ADR falls Friday, underperforms market - MSN
Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada
Adagene reports new findings at SITC meeting - Investing.com India
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau
Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire
Adagene's ADG126 Shows Breakthrough Results in Cancer Treatment, Outperforms Ipilimumab | ADAG Stock News - StockTitan
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene reports promising cancer therapy results - Investing.com
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan
Anheuser-Busch InBev S.A. ADR rises Thursday, outperforms market - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World
Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire
Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World
Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in June - Defense World
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Yahoo Finance
Adagene To Participate In The SVB Leerink 11th Annual Global Healthcare Conference - Barchart
Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast - Defense World
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - Quantisnow
Adagene Announces Updates to its Board of Directors - Quantisnow
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million - Quantisnow
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):